College Station, Texas
October 2, 2002

ProdiGene, Inc., a pioneer in recombinant protein development and manufacturing from transgenic plant systems, has embarked on a restructuring plan designed to enable ProdiGene to move forward with its commercialized products and strategic collaborations. As part of the plan, ProdiGene eliminated several positions that were no longer considered key to the core focus of the Company.

"The current market conditions have forced us to place more emphasis on generating sales with our core products, Trypzean(TM) (recombinant trypsin) and recombinant Aprotinin, which are both in high demand as non-animal sourced proteins used in the pharmaceutical industry," said Anthony G. Laos, President and CEO of ProdiGene.

ProdiGene, headquartered in College Station, Texas, is a private biotechnology company that is developing and manufacturing industrial and pharmaceutical proteins from a transgenic plant technology platform. ProdiGene, as the first and only company to produce and market a recombinant protein from a transgenic plant system, is well positioned to capitalize on the opportunities in the large and expanding recombinant protein markets. The Company has collaborations with several leading biotechnology and pharmaceutical companies.